t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

(2014) M. V. Ramana Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

(2014) N I Herath et al.   Blood Cancer Journal

Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma

(2013) Atsushi Inagaki et al.   LEUKEMIA RESEARCH

t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome

(2013) Gang An et al.   LEUKEMIA RESEARCH

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

(2010) H. Avet-Loiseau et al.   BLOOD

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma

(2007) J Yeung et al.   JOURNAL OF CLINICAL PATHOLOGY